- Home
- RMAX vs RPID Comparison
RMAX vs RPID Comparison
Compare RMAX & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- RPID
- Stock Information
- Founded
- RMAX 1973
- RPID 2006
- Country
- RMAX United States
- RPID United States
- Employees
- RMAX N/A
- RPID N/A
- Industry
- RMAX Real Estate
- RPID Medical Specialities
- Sector
- RMAX Finance
- RPID Health Care
- Exchange
- RMAX Nasdaq
- RPID Nasdaq
- Market Cap
- RMAX 151.5M
- RPID 155.6M
- IPO Year
- RMAX 2013
- RPID 2021
- Fundamental
- Price
- RMAX $7.44
- RPID $3.44
- Analyst Decision
- RMAX Hold
- RPID Buy
- Analyst Count
- RMAX 2
- RPID 1
- Target Price
- RMAX $9.75
- RPID $8.00
- AVG Volume (30 Days)
- RMAX 155.1K
- RPID 159.8K
- Earning Date
- RMAX 05-01-2025
- RPID 05-09-2025
- Dividend Yield
- RMAX N/A
- RPID N/A
- EPS Growth
- RMAX N/A
- RPID N/A
- EPS
- RMAX 0.44
- RPID N/A
- Revenue
- RMAX $303,865,000.00
- RPID $29,645,000.00
- Revenue This Year
- RMAX N/A
- RPID $18.54
- Revenue Next Year
- RMAX $1.59
- RPID $20.55
- P/E Ratio
- RMAX $16.65
- RPID N/A
- Revenue Growth
- RMAX N/A
- RPID 28.36
- 52 Week Low
- RMAX $6.90
- RPID $0.58
- 52 Week High
- RMAX $14.31
- RPID $4.04
- Technical
- Relative Strength Index (RSI)
- RMAX 42.98
- RPID 64.40
- Support Level
- RMAX $7.15
- RPID $3.15
- Resistance Level
- RMAX $7.63
- RPID $3.50
- Average True Range (ATR)
- RMAX 0.22
- RPID 0.22
- MACD
- RMAX -0.01
- RPID 0.01
- Stochastic Oscillator
- RMAX 33.17
- RPID 59.49
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.